First Biosimilar Approved in US: Filgrastim-sndz (Zarxio)First Biosimilar Approved in US: Filgrastim-sndz (Zarxio)

The first biosimilar product approved in the United States is filgrastim-sndz (Zarxio, Sandoz/Novartis), which was found to be similar to Amgen's Neupogen. News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news